Tissue Regenix Plc of the UK said that a preclinical study of its tissue regeneration technology showed a better performance than a competitor bovine-derived matrix. The study results were published in the open-access journal, PLoS.
The Karolinska University Hospital and GE Healthcare Life Sciences have started a joint research collaboration to address some of the issues associated with the manufacture and development of new cell therapies. Financial terms weren’t given.
Research published online in the journal Cell Stem Cell suggests that inhibiting a protein that regulates cell signalling could mitigate the process of ageing in haematopoietic stem cells (HSCs), key support mechanisms for blood cells and for the immune system.
Shire Plc has reached an agreement to acquire substantially all of the assets of privately-held Pervasis Therapeutics Inc of Cambridge, Massachusetts which has a clinical-stage, cell-based therapy for enhancing blood vessel repair.
Researchers from the US and Canada have reported generating a new type of cell line, endodermal progenitor cells, which they say could be used as a new tool for modeling human disease including diabetes and liver disease.
A team of experts in advanced therapies has concluded that developers of cell, gene and tissue-engineered therapies may need more support from the regulatory authorities in translating their discoveries into products for possible commercial use.
Promethera Biosciences SA, which is developing a therapy for liver disease using allogeneic stem cells derived from healthy adult human livers, has raised €23.6 million in a series B financing round that included four corporate investors.
Two UK institutions have stepped up their support for gene therapy with a £3.1 million award to a consortium that is investigating an experimental treatment for cystic fibrosis. The therapy is poised to enter Phase 2 development.
Therapies derived from human embryonic stem (hES) cells promise to be the most stable and cost-effective modality for future medicines and deserve support from public and private funders, according to a commentary in The Lancet.
The US Food and Drug Administration has approved an allogeneic cell therapy- the first of its kind – to treat vascular wounds caused by surgery to treat mucogingival conditions in adults. The product, Gintuit, was developed by Organogenesis Inc of Massachusetts, US.